Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/28/2021 07/29/2021 07/30/2021 08/02/2021 08/03/2021 Date
83.98(c) 83.52(c) 83.88(c) 83.77(c) 83.48 Last
2 413 522 2 778 435 3 009 511 2 051 836 2 834 575 Volume
+0.84% -0.55% +0.43% -0.13% -0.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 51 982 M - -
Net income 2021 9 881 M - -
Net Debt 2021 22 970 M - -
P/E ratio 2021 18,3x
Yield 2021 3,94%
Sales 2022 54 161 M - -
Net income 2022 10 702 M - -
Net Debt 2022 16 519 M - -
P/E ratio 2022 16,8x
Yield 2022 4,07%
Capitalization 203 B 225 B -
EV / Sales 2021 4,35x
EV / Sales 2022 4,06x
Nbr of Employees 109 000
Free-Float 87,4%
More Financials
Company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and... 
Sector
Pharmaceuticals
Calendar
09/30Investor Day
More about the company
Ratings of Novartis AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NOVARTIS AG
10:40aIONIS PHARMACEUTICALS : discovered pelacarsen continues to advance as potential ..
AQ
07:37aBAUSCH HEALTH : Reports Q2 Revenue US$2.1 Billion; Plans To Pursue An IPO of Sol..
MT
07:03aNOVARTIS : announces lift of partial clinical trial hold and plans to initiate a..
PU
06:46aNovartis Gets FDA Approval to Proceed With Trials for Muscular Atrophy Treatm..
DJ
05:58aNOVARTIS : Says FDA Lifts Partial Hold on Clinical Trial of Spinal Muscular Atro..
MT
01:48aNOVARTIS : to Launch New Study of Neuromuscular Disease Drug After US FDA Lifts ..
MT
01:15aPRESS RELEASE : Novartis announces lift of partial -2-
DJ
01:15aPRESS RELEASE : Novartis announces lift of partial clinical trial hold and plans..
DJ
01:15aNovartis announces lift of partial clinical trial hold and plans to initiate ..
DJ
01:15aNovartis Announces Lift of Partial Clinical Trial Hold and Plans to Initiate ..
CI
08/02IONIS PHARMACEUTICALS : Says Phase 3 Trial of Pelacarsen for Reducing Recurrent ..
MT
07/29Rubius Therapeutics Taps Dannielle Appelhans as Chief Operating Officer
DJ
07/28XOMA : Secures FDA's Orphan Drug Designation for Investigational Pancreatic Canc..
MT
07/28GLOBAL MARKETS LIVE : Apple, Alphabet, Facebook, Pfizer, McDonald's...
07/28XOMA Gets Orphan Drug Designation for Pancreatic Cancer Treatment
DJ
More news
News in other languages on NOVARTIS AG
11:47aAktien Schweiz schließen kaum verändert - Oerlikon gesucht
05:31aBourse Zurich: le SMI s'est offert la marque des 12'200 points
05:31aAktien Schweiz: SMI erstmals über 12'200 Punkten
03:47aNovartis-Aktien fester nach FDA-Entscheid zu gestoppter Zolgensma-Studie
03:35aNOVARTIS : levée de suspension partielle pour des essais
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 83,48 $
Average target price 105,60 $
Spread / Average Target 26,5%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.14%225 528
JOHNSON & JOHNSON9.46%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.19.42%246 075
ELI LILLY AND COMPANY46.06%224 166
NOVO NORDISK A/S36.15%212 792